iPS Cell Disease Modeling
Disease in a Dish
The availability of donor-specific induced pluripotent stem (iPS) cells, coupled with gene-editing techniques and genome-wide association studies (GWAS), is enabling new insights into the molecular basis and mechanisms of human disease. To enable you to rapidly and reproducibly implement these cellular disease models, Cellular Dynamics provides cryopreserved iPSC-derived cell types that can be produced from a diverse bank of iPS cells comprised of diseased genotypes with introduced or corrected mutations, as well as donor cohorts.
- Reproducible research: High purity and rigorous quality control to ensure the same performance with every batch
By employing heavily qualified materials, optimized differentiation processes, and rigorous quality procedures, CDI manufactures cells that work the same every time, ensuring research can be replicated between wells, experiments, and labs.
- Human relevance: More accurately mimic disease processes with species-specific results
The large number of drug candidates that are effective in mice but not humans clearly demonstrates a gap between animal models of disease and clinical translation. While animal models of disease offer some advantages, such as the ability to observe behavioral phenotypes, CDI’s iPSC-derived human cells provide physiologically relevant disease models, overcoming potential species-specific differences.
- Rapid results: Get results faster with cryopreserved cells. Just thaw, plate, and assay
iPSC-derived cellular models can be difficult to implement due to laborious and lengthy differentiation protocols, e.g. ~4 weeks for dopaminergic neurons and even longer for astrocytes. CDI’s ready-to-use cells – just thaw, plate, and assay – can accelerate your research by enabling you to complete more experiments in less time.
- Choice in genetic background: Differentiated cells available from a diverse collection including diseased lines and isogenic controls
CDI is engaged in several large-scale iPS cell reprogramming and banking projects making iPS cells and their differentiated progeny broadly available from thousands of backgrounds representing typical human diversity and various disease states. Additionally, by introducing or correcting mutations, CDI is making isogenic controls available for diseased lines. Use our searchable database to quickly find iPSC-derived cells with specific disease mutations and their isogenic controls and avoid the lengthy processes of donor recruitment, reprogramming, and differentiation optimization.
Diseases are typically modeled in vitro in three ways:
iPS cells are generated from donors with specific genotypes and differentiated into cell types associated with the disease of interest. As a control, iPS cells from apparently healthy normal (AHN) donors are differentiated into the same cell type and phenotypic and functional analyses are compared. This approach is particularly helpful with diseases of unknown or complex genetic backgrounds. To find control lines for this approach, visit our iCell® portfolio consisting of cells differentiated from AHN donors. iPSC-derived cells from an extensive collection of donors with specific diseases are available in our MyCell® portfolio.
In cases where a specific mutation is known to be involved in a disease state, the engineered approach can be used to study the effect of the mutation in as precise a model as possible. Cells from either AHN or donors with a confirmed disease mutation can have that mutation edited with CRISPR technology to either introduce or correct the mutation, respectively. The two isogenic cell lines created can then be differentiated into the cell type of interest, with the single mutation being the sole variable being studied. iPSC-derived cells with specific disease mutations and their isogenic controls are available in our MyCell portfolio.
In addition, a disease state can be induced by subjecting iPSC-derived cells from AHN donors to specific culture conditions. To view the cell types available from AHN donors, visit our iCell portfolio. For examples of how to induce a disease state through culture conditions, view our application protocols on modeling cardiac hypertrophy.
To learn more about the cutting-edge research using iPSC-derived disease models, see the applications, below.